UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

SP 123 Overcoming drug resistance in melanoma

European journal of cancer (1990), 2011, Vol.47, p.S5-S5

Sosman, J.A

2011

Volltextzugriff (PDF)

90 Tumor infiltrating leukocyte subpopulations as a biomarker of response and resistance to targeted therapy in patients with BRAF mutation-positive metastatic melanoma

European journal of cancer (1990), 2014-11, Vol.50, p.33-34

2014

Volltextzugriff (PDF)

3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S663-S663

2015

Volltextzugriff (PDF)

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

European journal of cancer (1990), 2015-09, Vol.51, p.S721-S721

2015

Volltextzugriff (PDF)

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

European journal of cancer (1990), 2015-09, Vol.51, p.S708-S708

2015

Volltextzugriff (PDF)

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Annals of oncology, 2017-02, Vol.28 (2), p.368-376

2017

Volltextzugriff (PDF)

162 Resistance to RAF Inhibitors Due to RAS-independent Dimerization of BRAF(V600E) Splicing Variants

European journal of cancer (1990), 2012-11, Vol.48, p.49-50

2012

Volltextzugriff (PDF)

270 The Impact of a Tissue Acquisition Program On Research in Molecular Targeted Therapy of Melanoma

European journal of cancer (1990), 2012-11, Vol.48, p.83-83

2012

Volltextzugriff (PDF)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Oncogene, 2016-03, Vol.35 (10), p.1225-1235

2016

Volltextzugriff (PDF)

Outcomes in BRAFV600e-Mutant Melanoma Brain Metastases Managed with Radiosurgery: A Multi-Institutional Assessment of Craniotomy Mitigation

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.e212-e212

2018

Volltextzugriff (PDF)

Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post–Stem-Cell Infusion

Journal of clinical oncology, 2001-02, Vol.19 (3), p.634-644

2001

Volltextzugriff (PDF)

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

Annals of oncology, 2016-10, Vol.27, p.vi379-vi379

2016

Volltextzugriff (PDF)

Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma

Annals of oncology, 2016-10, Vol.27, p.vi381-vi381

2016

Volltextzugriff (PDF)

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

Annals of oncology, 2017-10, Vol.28 (10), p.2581-2587

2017

Volltextzugriff (PDF)

23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

European journal of cancer supplements, 2009, Vol.7 (3), p.13-13

2009

Volltextzugriff (PDF)

Immune Correlates and Long Term Follow Up of a Phase Ia Study of Mpdl3280A, an Engineered Pd-L1 Antibody, in Patients with Metastatic Renal Cell Carcinoma (Mrcc)

Annals of oncology, 2014-09, Vol.25, p.iv280

2014

Volltextzugriff (PDF)

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

Annals of oncology, 2012-09, Vol.23, p.ix158

2012

Volltextzugriff (PDF)

4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers

European journal of cancer supplements, 2007, Vol.5 (4), p.301-301

2007

Volltextzugriff (PDF)

7004 ORAL Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma

European journal of cancer supplements, 2007, Vol.5 (4), p.396-396

2007

Volltextzugriff (PDF)

Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial

Annals of oncology, 2014-09, Vol.25, p.iv375

2014

Volltextzugriff (PDF)

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Annals of oncology, 2015-02, Vol.26 (2), p.415-421

2015

Volltextzugriff (PDF)

Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM)

Annals of oncology, 2012-09, Vol.23, p.ixe19

2012

Volltextzugriff (PDF)

809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv280-iv280

2014

Volltextzugriff (PDF)

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2with interferon α-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population

Annals of oncology, 2002-04, Vol.13 (4), p.606-613

2002

Volltextzugriff (PDF)

1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv375-iv376

2014

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(10)
Female
(6)
Humans
(6)
Adult
(5)
Middle Aged
(5)
Aged
(4)
Male
(4)
Melanoma
(4)
Life Sciences & Biomedicine
(3)
Melanoma - Drug Therapy
(3)
Mutation
(3)
Oncology
(3)
Proto-Oncogene Proteins B-Raf - Genetics
(3)
Science & Technology
(3)
Aged, 80 And Over
(2)
Antineoplastic Agents
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Biological And Medical Sciences
(2)
Drug Administration Schedule
(2)
Immunotherapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SP 123 Overcoming drug resistance in melanoma

90 Tumor infiltrating leukocyte subpopulations as a biomarker of response and resistance to targeted therapy in patients with BRAF mutation-positive metastatic melanoma

3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

162 Resistance to RAF Inhibitors Due to RAS-independent Dimerization of BRAF(V600E) Splicing Variants

270 The Impact of a Tissue Acquisition Program On Research in Molecular Targeted Therapy of Melanoma

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Outcomes in BRAFV600e-Mutant Melanoma Brain Metastases Managed with Radiosurgery: A Multi-Institutional Assessment of Craniotomy Mitigation

Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post–Stem-Cell Infusion

Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone

Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma

Immune Correlates and Long Term Follow Up of a Phase Ia Study of Mpdl3280A, an Engineered Pd-L1 Antibody, in Patients with Metastatic Renal Cell Carcinoma (Mrcc)

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers

7004 ORAL Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma

Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM)

809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2with interferon α-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population

1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL

Suchergebnisse filtern